MO01.43 Examining the Impact of Tislelizumab Added to Platinum Doublet Chemotherapy on Health-Related Quality of Life in Patients with Non-Squamous NSCLC

S. Lu,Y. Yu,G. Barnes,X. Qiu,Y. Bao,J. Li,B. Tang

DOI: https://doi.org/10.1016/j.jtho.2020.10.147

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:Platinum plus pemetrexed chemotherapy is one of the most widely accepted treatment options for patients with non-squamous non-small cell lung cancer (nSQ-NSCLC) without EGFR mutations or ALK rearrangements. This study is based on the clinical trial (NCT03663205) assessing the effects of the addition of tislelizumab to platinum doublet chemotherapy on the health-related quality of life (HRQoL) of patients with nSQ-NSCLC. Patients in this open-label, multicenter Phase 3 study were randomized to two arms: tislelizumab + platinum-pemetrexed (Arm T+PP) or platinum-pemetrexed alone (Arm PP). HRQoL was measured using EORTC-QLQ-C30 global health status (GHS/qol) and QLQ-LC13. Mean score changes from baseline to week 12 (cycle 5, combination therapy stage) and week 18 (cycle 7, maintenance stage) were compared between the two ar A total of 334 nSQ-NSCLC patients were randomized (Arm T+PP: n=223; Arm PP; n=111). Patients were 74% male with a median age of 61 years (range 25 - 75). Baseline characteristics were comparable across the two treatment arms and were representative of the target patient population. GHS/QoL improved in Arm T+PP at cycle 5 [mean change (standard deviation) = 0.7(23.06)] and cycle 7 [2.8(19.57)] and declined in Arm PP at both timepoints [cycle 5: -3.8(15.53); cycle 7: -3.4(18.71)]. Furthermore, patients in Arm T+PP experienced larger reductions in coughing, chest pain, dyspnea, and arm/shoulder pain symptoms; whereas, Arm PP experienced numerically higher reductions in “pain in other parts”. Other symptoms remained similar between the two groups. (Table 1). The addition of tislelizumab to platinum-based chemotherapy was associated with improvements in nSQ-NSCLC patients’ HRQoL, especially in general health status and most importantly in disease specific symptoms of coughing, chest pain, and dyspnea.